22 January 2025 - New report will highlight opportunities to improve affordability and access, and demonstrate the importance of having a system that pays for value.

The ICER today announced a new analysis it plans to release on an annual basis titled the “Launch Price and Access Report” which will examine launch pricing for FDA approved treatments. This report will review the affordability and access of the treatments and their value to the overall health system.

Read ICER Announcement